Business Context and Reporting Period
Company: Quantum-Si Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 3, 2025
Reporting Period: Event-based report regarding a material definitive agreement entered into on July 3, 2025.
Key Financial Metrics and Transaction Details
This filing details a Registered Direct Offering rather than periodic financial results. Key transaction metrics include:
- Gross Proceeds: Approximately $50 million (before fees and expenses).
- Securities Issued:
- 18,200,000 shares of Class A common stock at $1.67 per share.
- Pre-funded warrants to purchase 11,740,119 shares of common stock at an exercise price of $0.0001 per share.
- Placement Fee: 6.0% of gross proceeds payable to A.G.P./Alliance Global Partners.
- Expected Closing Date: July 8, 2025.
Use of Proceeds: Future product development (including the Proteus TM platform), general commercialization, manufacturing development, research and development, working capital, capital expenditures, and general and administrative expenses.
Material Changes and Terminations
Termination of Prior Agreement: The Company terminated its Equity Distribution Agreement with Canaccord Genuity LLC, effective July 3, 2025.
- Shares Sold Under Prior Agreement: 23,425,650 shares.
- Gross Proceeds from Prior Agreement: $36.2 million.
- Remaining Authorized Amount at Termination: $38.8 million.
Lock-Up Restrictions: The Company is restricted from issuing or announcing the issuance of common stock or equivalents for 45 days following the closing of the Registered Direct Offering, with specific exceptions for exempt issuances and employee benefit plans.
Outlook, Risks, and Management Commentary
Management Commentary: The Company intends to utilize the net proceeds to accelerate product development and commercialization efforts. The transaction is structured as a registered direct offering with an institutional investor.
Risks and Contingencies:
- Closing Conditions: The offering is subject to the satisfaction of customary closing conditions.
- Beneficial Ownership Limitations: The Purchaser's ability to exercise pre-funded warrants is subject to beneficial ownership limitations.
- Dilution: The issuance of 18.2 million shares and pre-funded warrants for 11.7 million shares will result in significant dilution to existing shareholders.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $50 million gross proceeds on or after July 8, 2025.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific representations, warranties, and indemnification obligations.
- Monitor the Company's cash burn rate and runway extension relative to the stated use of proceeds for the Proteus TM platform.
- Assess the impact of the 45-day lock-up period on the Company's ability to raise additional capital in the near term.
- Confirm the exact number of shares outstanding post-closing to calculate the precise dilution effect.